Jul 17, 2024, 13:52 by ASAM Weekly Editors

Benzodiazepine use in relation to long-term dementia risk

Jul 11, 2024, 14:05 by ASAM Weekly Editors

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial

Jul 5, 2024, 16:54 by ASAM Weekly Editors

Global status report on alcohol and health and treatment of substance use disorders

Jul 5, 2024, 16:28 by Molly McGrath

ASAM Advocacy has developed seven fundamental tips for op-ed writing to assist members.

Jun 27, 2024, 17:00 by Molly McGrath

Twenty four organizations signed a letter, spearheaded by Mental Health America, requesting $40 million for the Employee Security Benefits Administration (EBSA) within the Department of Labor (DOL) in the FY 2025 Labor-Health and Human Services (HHS) appropriations bill to review health plans' parity compliance analyses.

Jun 27, 2024, 06:45 by ASAM Weekly Editors

Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths

Jun 26, 2024, 13:39 by Molly McGrath

ASAM joined a letter signed by 40 organizations requesting the Departments of Health and Human Services, Labor, and Treasury finalize the 2023 proposed parity regulations.

Jun 20, 2024, 11:33 by ASAM Weekly Editors

Piloting a Hospital-Based Rapid Methadone Initiation Protocol for Fentanyl

Jun 20, 2024, 11:31 by ASAM Weekly Editors

Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

Jun 20, 2024, 11:29 by ASAM Weekly Editors

Innovation and adaptation: The rise of a fentanyl smoking culture in San Francisco

Jun 13, 2024, 13:44 by Kelly Corredor

ASAM & ACAAM Comment on CMS Rule for GME Fellowships

Jun 13, 2024, 13:29 by Kelly Corredor

Letter to HRSA on reentry program guidance

Jun 13, 2024, 00:31 by Molly McGrath

On June 10th, the Michigan Society of Addiction Medicine (MISAM) sent a comment letter to the Michigan Department of Health and Human Services regarding a proposed policy expanding the services provided by Substance Use Disorder (SUD) Health Homes. Specifically, this proposal would add simulant use disorder and alcohol use disorder as eligible diagnoses for reimbursement.

Jun 7, 2024, 14:15 by Kelly Corredor

Sign-on letter to CMS requests more information and transparency on network adequacy, reimbursement rates and practices, utilization management, cost-sharing, and supplemental benefits.

Jun 7, 2024, 14:07 by Molly McGrath

ASAM signed a letter spearheaded by the Campaign for Tobacco-Free Kids, sent to the leadership of the House Appropriations Committee, urging their approval of the full authorized level of tobacco user fees, and their opposition any efforts to weaken or alter the Food and Drug Administration's authority over tobacco products in the appropriations process.

Jun 6, 2024, 17:46 by Kelly Corredor

New ASAM resource on Medicare coverage of injectable addiction treatment medications.

Jun 3, 2024, 22:29 by Molly McGrath

The recent article “Has Fentanyl Peaked?” in The New York Times had me asking a different question: How much do we care about Americans with addiction, dying at unprecedented numbers from an increasingly lethal drug supply?

May 28, 2024, 16:33 by Molly McGrath

A group of over fifty stakeholders and leaders called on the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder (StimUD).

May 28, 2024, 15:02 by ASAM Weekly Editors

Rapid Initiation of Injection Naltrexone for Opioid Use Disorder

May 22, 2024, 15:14 by Molly McGrath

On May 17th, Louisiana Society of Addiction Medicine (LASAM) sent a letter of opposition to SB 276 ahead of its consideration by the Louisiana House of Representatives. SB 276 would designate mifepristone as a controlled substance.